AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19221726 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg, 3 times a day for 7 days)
Number of subjects: 12
Study 19221726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17591036 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Enterococcus faecalis T‐110, Clostridium butyricum TO‐A, and Bacillus mesentericus TO‐A) administered perioperatively, starting immediately after admission, 3 to 15 days before the operation, and continued until hospital discharge.
Number of subjects: 70
Study 17591036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 70
Study 17591036 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 70
Study 15040824 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D Program (1000 mg of elemental calcium as calcium carbonate and 400 IU of vitamin D3 daily)
Number of subjects: 9605
Study 15040824 — intervention group
Group type: COMPARATOR
Intervention: Environmental and Health Program (evaluation and suggestions for improvement of the domestic environment)
Number of subjects: 9605
Study 10632537 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of styrene maleic acid neocarzinostatin in 4 ml of Lipiodol (Group A)
Number of subjects: 37
Study 10632537 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of epirubicin in 4 ml of Lipiodol (Group B)
Number of subjects: 37
Study 11517475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischemic disorders of cerebral circulation
Number of subjects: 45
Study 8211540 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg oral)
Number of subjects: 59
Study 8211540 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (250 mg intramuscular)
Number of subjects: 59
Study 3546170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-living promastigote vaccine
Number of subjects: 0
Study 3546170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31682572 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) blended with weekly real-time therapist chat sessions for 8 weeks
Number of subjects: 70
Study 31682572 — intervention group
Group type: COMPARATOR
Intervention: Minimal attention control
Number of subjects: 70
Study 27942857 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized 3-week exercise program with two additional 1-week inpatient stays after 4 and 8 months
Number of subjects: 194
Study 27942857 — intervention group
Group type: COMPARATOR
Intervention: 3-week rehabilitation program without follow-up care
Number of subjects: 194
Study 27942857 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Number of subjects: 194
Study 25683748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nitrate (HN) diet
Number of subjects: 19
Study 25683748 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 19
Study 23808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (dose titrated during 2 weeks)
Number of subjects: 31
Study 23808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 31
Study 23808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ivabradine + atenolol (in half doses)
Number of subjects: 31
Study 23808298 — intervention group
Group type: COMPARATOR
Intervention: Ivabradine (15 mg/day)
Number of subjects: 31
Study 23808298 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (control group)
Number of subjects: 31
Study 21861038 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to low-molecular-weight heparin (LMWH) - enoxaparin: 1 mg/kg 2x/day before ablation, and 0.5 mg/kg 2x/day after ablation
Number of subjects: 140
Study 21861038 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of warfarin with therapeutic INR (between 2.0 and 3.0)
Number of subjects: 140
Study 18444883 — intervention group
Group type: EXPERIMENTAL
Intervention: VCL‐CB01 vaccine (1- or 5-mg doses) administered on a 0-, 2-, and 8-week schedule
Number of subjects: 44
Study 18444883 — intervention group
Group type: EXPERIMENTAL
Intervention: VCL‐CB01 vaccine (5-mg doses) administered on a 0-, 3-, 7-, and 28-day schedule
Number of subjects: 44
Study 16935602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tungsten powder balloon
Number of subjects: 24
Study 16935602 — intervention group
Group type: COMPARATOR
Intervention: Mercury-containing device
Number of subjects: 24
Study 12963561 — intervention group
Group type: EXPERIMENTAL
Intervention: EX + WL
Number of subjects: 53
Study 12963561 — intervention group
Group type: EXPERIMENTAL
Intervention: EX only
Number of subjects: 53
Study 12963561 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study 11269896 — intervention group
Group type: EXPERIMENTAL
Intervention: Local conjunctival immunotherapy (LCIT) with standardized dermatophagoides pteronyssinus (Dp) extracts, administered daily for 6 months at increasing concentrations starting from 10 AU/ml to a maintenance dose of 1,000 AU/ml.
Number of subjects: 24
Study 11269896 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, administered daily for 6 months.
Number of subjects: 24
Study 9109894 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/d tiagabine
Number of subjects: 162
Study 9109894 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg/d tiagabine
Number of subjects: 162
Study 9109894 — intervention group
Group type: EXPERIMENTAL
Intervention: 56 mg/d tiagabine
Number of subjects: 162
Study 9109894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 8239351 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 61
Study 8239351 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 3084705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-monitored electroconvulsive therapy (MMECT)
Number of subjects: 54
Study 3084705 — intervention group
Group type: COMPARATOR
Intervention: Conventional electroconvulsive therapy (CECT)
Number of subjects: 54
Study 30892820 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD defined using a liver‐spleen ratio (L/S ratio) ≤1.1 on unenhanced abdominal CT scanning
Number of subjects: 4002
Study 30892820 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index, waist circumference, serum triglyceride, alanine transaminase, and hemoglobin A1c
Number of subjects: 4002
Study 30892820 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher annual household income and systolic blood pressure for men
Number of subjects: 4002
Study 30892820 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum uric acid and red meat intake and lower physical activity levels for women
Number of subjects: 4002
Study 30892820 — intervention group
Group type: EXPERIMENTAL
Intervention: L/S ratio ≤1.1
Number of subjects: 4002
Study 30630798 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal-epidural anesthesia with intravenous injection of dexmedetomidine
Number of subjects: 100
Study 30630798 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Control group)
Number of subjects: 100
Study 27117038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 127
Study 24521108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 719
Study 24521108 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole 0.5 mg
Number of subjects: 719
Study 24521108 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole 0.25 mg
Number of subjects: 719
Study 24521108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 719
Study 23525418 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 6983
Study 23525418 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy (experienced vs naïve)
Number of subjects: 6983
Study 23525418 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic region
Number of subjects: 6983
Study 20597245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg, one stick per hour)
Number of subjects: 29
Study 20597245 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 29
Study 20597245 — intervention group
Group type: COMPARATOR
Intervention: No cigarettes/no gum
Number of subjects: 29
Study 20597245 — intervention group
Group type: COMPARATOR
Intervention: Nicotine cigarettes
Number of subjects: 29
Study 19075486 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic training (64 patients)
Number of subjects: 125
Study 19075486 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls, 61 patients)
Number of subjects: 125
Study 16636023 — intervention group
Group type: EXPERIMENTAL
Intervention: Allowing wounds to be uncovered and wet in the first 48 hours (n = 415)
Number of subjects: 857
Study 16636023 — intervention group
Group type: COMPARATOR
Intervention: Standard management of keeping wounds dry and covered (n = 442)
Number of subjects: 857
Study 12851527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cardiovascular risk factor management for 6 months
Number of subjects: 132
Study 12851527 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilatation (FMD)
Number of subjects: 132
Study 12851527 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma von Willebrand factor (vWF)
Number of subjects: 132
Study 11099628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.80 mg/kg/day for group 1 and 2; 0.72 mg/kg/day for group 3)
Number of subjects: 252
Study 11099628 — intervention group
Group type: COMPARATOR
Intervention: Control (no cisapride)
Number of subjects: 252
Study 11099628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 252
Study 7841817 — intervention group
Group type: COMPARATOR
Intervention: Gamma Knife capsulotomy
Number of subjects: 0
Study 2830968 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin fraction V (60 mg/m2 s.c. twice weekly) during induction chemotherapy and radiation therapy
Number of subjects: 91
Study 2830968 — intervention group
Group type: COMPARATOR
Intervention: No thymosin
Number of subjects: 91
Study 31515562 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neurofilament light chain (sNfL) levels measured using an ultrasensitive single‐molecule array assay (Simoa)
Number of subjects: 60
Study 31515562 — intervention group
Group type: EXPERIMENTAL
Intervention: Presymptomatic sNfL levels
Number of subjects: 60
Study 31515562 — intervention group
Group type: EXPERIMENTAL
Intervention: Postonset sNfL levels
Number of subjects: 60
Study 28592218 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact aspiration
Number of subjects: 380
Study 28592218 — intervention group
Group type: COMPARATOR
Intervention: Stent retriever
Number of subjects: 380
Study 28463718 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (CACR) therapy
Number of subjects: 33
Study 28463718 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 33
Study 28129987 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine
Number of subjects: 732
Study 28129987 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 732
Study 23953136 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 390
Study 20538494 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 90
Study 20538494 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 90
Study 20538494 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 19397113 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-radiographic method of measuring knee alignment
Number of subjects: 0
Study 19397113 — intervention group
Group type: COMPARATOR
Intervention: Radiographic method of measuring knee alignment
Number of subjects: 0
Study 17885293 — intervention group
Group type: EXPERIMENTAL
Intervention: ANRS GIS
Number of subjects: 744
Study 17885293 — intervention group
Group type: EXPERIMENTAL
Intervention: DMC GIS
Number of subjects: 744
Study 17885293 — intervention group
Group type: EXPERIMENTAL
Intervention: REGA GIS
Number of subjects: 744
Study 17885293 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford GIS
Number of subjects: 744
Study 15841581 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stent for bone reduction
Number of subjects: 10
Study 15841581 — intervention group
Group type: COMPARATOR
Intervention: No surgical stent (control group)
Number of subjects: 10
Study 11765387 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal education programme for couples (clinic-based)
Number of subjects: 0
Study 11765387 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based antenatal education programmes for expectant fathers
Number of subjects: 0
Study 9759796 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.01%
Number of subjects: 98
Study 9759796 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.05%
Number of subjects: 98
Study 9759796 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1%
Number of subjects: 98
Study 9759796 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.15%
Number of subjects: 98
Study 9759796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 7882486 — intervention group
Group type: EXPERIMENTAL
Intervention: 115-J (70-microF) biphasic pulse
Number of subjects: 30
Study 7882486 — intervention group
Group type: EXPERIMENTAL
Intervention: 130-J (105-microF) biphasic pulse
Number of subjects: 30
Study 7882486 — intervention group
Group type: COMPARATOR
Intervention: 200-J (36-microF, 28-mH) damped sine wave pulse
Number of subjects: 30
Study 2164477 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta-blocker)
Number of subjects: 10
Study 2164477 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-selective blocker)
Number of subjects: 10
Study 2164477 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 10
Study 371649 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation with halothane
Number of subjects: 100
Study 371649 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation with fentanyl
Number of subjects: 100
Study 31937915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - 10×1-min intervals at 90-100% peak workload, 3 times per week for 6 weeks
Number of subjects: 28
Study 31937915 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT) - 30 min at 65-75% peak heart rate, 3 times per week for 6 weeks
Number of subjects: 28
Study 28277432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 ∼14.8%)
Number of subjects: 8
Study 28277432 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 8
Study 27486198 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored Internet Cancer Support Group (ICSG)
Number of subjects: 65
Study 27486198 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 25991461 — intervention group
Group type: EXPERIMENTAL
Intervention: Wraparound care initiated at the time of their visit for injury due to violence
Number of subjects: 0
Study 25991461 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 23706259 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group (flomoxef sodium every 12 hours for 3 days)
Number of subjects: 241
Study 23706259 — intervention group
Group type: COMPARATOR
Intervention: Non‐postoperative antibiotic group
Number of subjects: 241
Study 23706259 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group
Number of subjects: 241
Study 21744744 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g) + Folic acid (200 microg)
Number of subjects: 0
Study 21744744 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (200 microg)
Number of subjects: 0
Study 19560195 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-liquid opaquer (Sinfony, 3M ESPE) at 0.25 mm thickness
Number of subjects: 80
Study 19560195 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-liquid opaquer (Sinfony, 3M ESPE) at 0.50 mm thickness
Number of subjects: 80
Study 19560195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste opaquer (Cimara, Voco) at 0.25 mm thickness
Number of subjects: 80
Study 19560195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste opaquer (Monopaque, Ivoclar Vivadent) at 0.25 mm thickness
Number of subjects: 80
Study 19560195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste opaquer (Monopaque, Ivoclar Vivadent) at 0.50 mm thickness
Number of subjects: 80
Study 19560195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste opaquer (Cavex Experimental, Cavex) at 0.25 mm thickness
Number of subjects: 80
Study 19560195 — intervention group
Group type: EXPERIMENTAL
Intervention: Paste opaquer (Cavex Experimental, Cavex) at 0.50 mm thickness
Number of subjects: 80
Study 19560195 — intervention group
Group type: EXPERIMENTAL
Intervention: All opaquers
Number of subjects: 80
Study 16671489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventriculoperitoneal shunt with gravitational valve
Number of subjects: 51
Study 15289800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 28
Study 15289800 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 28
Study 11559340 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal drops dyed with methylene blue (0.1% v/v)
Number of subjects: 0
Study 11559340 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous sprays dyed with methylene blue (0.1% v/v)
Number of subjects: 0
Study 9427455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (Pa)
Number of subjects: 201
Study 9427455 — intervention group
Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine (Pw)
Number of subjects: 201
Study 7705531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose monophasic pill
Number of subjects: 80
Study 7705531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose monophasic pill
Number of subjects: 80
Study 7705531 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic pill
Number of subjects: 80
Study 7705531 — intervention group
Group type: COMPARATOR
Intervention: No therapy (expectant management)
Number of subjects: 80
Study 2884705 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tulobuterol/day
Number of subjects: 10
Study 2884705 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg fenoterol/day
Number of subjects: 10
Study 2884705 — intervention group
Group type: COMPARATOR
Intervention: Inhalative fenoterol
Number of subjects: 10
Study 2884705 — intervention group
Group type: COMPARATOR
Intervention: No treatment / pretreatment with oral fenoterol
Number of subjects: 10
Study 2884705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol and fenoterol treatment
Number of subjects: 10
Study 30123970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg BID plus regorafenib 160 mg QD
Number of subjects: 396
Study 30123970 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus regorafenib 160 mg QD
Number of subjects: 396
Study 27607858 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling
Number of subjects: 113
Study 27607858 — intervention group
Group type: COMPARATOR
Intervention: Burch retropubic urethropexy
Number of subjects: 113
Study 24771634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone (IV infusion every 12 hours)
Number of subjects: 66
Study 24771634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV infusion every 12 hours)
Number of subjects: 66
Study 24771634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ceftriaxone twice (IV infusion every 12 hours)
Number of subjects: 66
Study 22698562 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle-to-pulmonary artery shunt
Number of subjects: 546
Study 22698562 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock-Taussig shunt
Number of subjects: 546
Study 22698562 — intervention group
Group type: COMPARATOR
Intervention: Local standard of care
Number of subjects: 546
Study 20307829 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain packaging with varying degrees of brand elements removed and increased size of pictorial health warnings (30% to 80%)
Number of subjects: 0
Study 20307829 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain packaging with increased size of pictorial health warnings
Number of subjects: 0
Study 18435883 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rifamycin
Number of subjects: 48
Study 18435883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rifamycin treatment)
Number of subjects: 48
Study 16163871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2
Number of subjects: 9
Study 16163871 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1
Number of subjects: 9
Study 16163871 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Multipurpose
Number of subjects: 9
Study 12966123 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity/high duration
Number of subjects: 201
Study 12966123 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity/high duration
Number of subjects: 201
Study 12966123 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity/moderate duration
Number of subjects: 201
Study 12966123 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity/moderate duration
Number of subjects: 201
Study 11525344 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for the Drug‐Free Years (PDFY) curriculum
Number of subjects: 424
Study 11525344 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 424
Study 8806290 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav suspension (20 mg/kg amoxicillin, 5 mg/kg clavulanate potassium), orally three times a day for 14 days
Number of subjects: 162
Study 8806290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 1352828 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40